Asterias Biotherapeutics, Inc. (AST): Alfred D Kingsley , director of Asterias Biotherapeutics, Inc. purchased 4,000 shares on Jun 9, 2016. The Insider buying transaction was reported by the company on Jun 10, 2016 to the Securities and Exchange Commission. The shares were purchased at $2.93 per share for a total value of $11,720.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 17, 2016, Natale S Ricciardi (director) purchased 14,706 shares at $3.39 per share price.On May 17, 2016, Don M Bailey (director) purchased 88,235 shares at $3.39 per share price.Also, On May 17, 2016, Richard T. Lebuhn (director) purchased 15,000 shares at $3.39 per share price.On Sep 16, 2015, Jane Lebkowski (President of R&D) sold 4,912 shares at $6.00 per share price.
Shares of Asterias Biotherapeutics Inc (AST) ended Thursday, Jun 9, 2016 session in red amid volatile trading. The shares closed down -0.2 points or -6.39% at $2.93 with 2,60,089 shares getting traded. Post opening the session at $3.06, the shares hit an intraday low of $2.84 and an intraday high of $3.15 and the price vacillated in this range throughout the day. The company has a market cap of $131 M and the number of outstanding shares has been calculated to be 4,45,54,421 shares. The 52-week high of Asterias Biotherapeutics Inc is $9.56 and the 52-week low is $2.36.
Company has been under the radar of several Street Analysts.Asterias Biotherapeutics Inc is Initiated by Chardan Capital Markets to Buy and the brokerage firm has set the Price Target at $5.50. The Rating was issued on May 23, 2016.Asterias Biotherapeutics Inc is Initiated by Rodman & Renshaw to Buy and the brokerage firm has set the Price Target at $12. The Rating was issued on Apr 25, 2016.
Asterias Biotherapeutics Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company’s product development is focused primarily on AST-OPC1 and AST-VAC2. The Company’s lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).